JNJ Research Update — August 28, 2026
Updated Thesis
Johnson & Johnson is a diversified healthcare leader operating through Innovative Medicine and MedTech segments, with a strong portfolio spanning immunology, oncology, and medical devices. The company demonstrates high business quality with a durable competitive moat, evidenced by a 70.5% TTM gross margin, 25.7% ROE, and consistent revenue growth of 6.6% in the most recent quarter. However, earnings declined 52.4% in the most recent quarter, highlighting volatility, and the stock trades at a very expensive valuation regime with a P/E of 30.83 and P/S of 6.54.
The investment grade as of this refresh is C — average business quality. High-tier business, expensive valuation with 3.3% upside to fair value
Grade Change
In this research cycle, the investment grade for Johnson & Johnson moved from D to C. High-tier business, expensive valuation with 3.3% upside to fair value
Key Metrics at a Glance
- Revenue growth: +6.6% year over year
- Net margin: 21.5%
- Fair value upside: +3.3% to our estimate of $274
Current price: $265.77
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Johnson & Johnson remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full JNJ research →](/stocks/JNJ)